基本信息 产品详情 公司简介 推荐产品
网站主页 4,5-二(羟甲基)-2-苯基-1H-咪唑 化合物 WYC209
  • 化合物 WYC209|T5341|TargetMol

化合物 WYC209|T5341|TargetMol

WYC-209
2131803-90-0
248 1mg 起订
578 5mg 起订
913 10mg 起订
上海 更新日期:2024-12-12

TargetMol中国(陶术生物)

VIP3年
联系人:邵小姐
手机:4008200310 拨打
邮箱:marketing@tsbiochem.com

产品详情:

中文名称:
化合物 WYC209
英文名称:
WYC-209
CAS号:
2131803-90-0
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
纯度规格:
99.77%
产品类别:
抑制剂
货号:
T5341

Product Introduction

Bioactivity

名称WYC-209
描述WYC-209 inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs, IC50: 0.19 uM). It targets the retinoic acid receptor (RAR).
细胞实验Cell proliferation rate was measured by using MTT colorimetric assay. Cells were seeded in 3D soft fibrin gel in 96-well microplates at a density to maintain control (untreated) cells in an exponential phase of growth during the entire experiment. Cells were incubated with various concentrations of compounds for each time point followed by incubation with 50?μL MTT reagent for 3?h at 37?°C. After incubation, 150?μL MTT solvent was added and absorbance was measured at 570?nm. All experiments were repeated at least three times. The percentage of viable cells was calculated and averaged for each well: percent growth?=?(OD-treated cells/OD control cells)?×?100, cell proliferation at each time point is normalized to base line cell survival at the time of initial compound treatment (day 0).
动物实验Four- to six-week-old female and male C57BL/6 mice were used in mice experiment. Mice were randomized into different groups. In metastasis experiment, B16-F1 cell spheroids were selected from 3D 90-Pa fibrin gels and pipetted to single cells. These TRCs were harvested and the cell number was counted under microscopy. The cells were then suspended in PBS with appropriate cell density. Thirty thousand TRCs were intravenously injected into the tail vein of each wild-type C57BL/6 mouse. Five days later, inoculated mice were intravenous implanted with 0.022?mg/kg WYC-209, 0.22?mg/kg WYC-209, or 0.1% DMSO every two days. The mice were euthanized and examined for lung tumor formation at day 30. In treated TRCs injected in vivo experiments, B16-F1 cells were seeded into 3D 90-Pa fibrin gels and treated with 10?μM WYC-209 or 0.1% DMSO on day 3, then isolated treated TRCs colonies on day 5 and pipetted into single cell. 30,000 of TRCs were intravenously injected into the tail vein of each wild-type C57BL/6 mouse. No blinding was performed in the mice experiments.
体外活性WYC-209 inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs), with an IC50 of 0.19?μM in a dose-dependent manner. WYC-209 also inhibits proliferation of TRCs of human melanoma, lung cancer, ovarian cancer, and breast cancer in culture.
体内活性WYC-209 abrogates 87.5% of lung metastases of melanoma TRCs in immune-competent wild-type C57BL/6 mice at 0.22?mg?kg-1 without showing apparent toxicity.
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度DMSO : 80 mg/mL (217.13 mM)
H2O : Insoluble
关键字Apoptosis | WYC 209 | Retinoid X receptors | Inhibitor | Retinoic acid receptors | WYC-209 | Autophagy | RAR/RXR | inhibit
相关产品Guanidine hydrochloride | Naringin | Valproic Acid | L-Glutamic acid | Gefitinib | Hydroxychloroquine | Dextran sulfate sodium salt (MW 4500-5500) | Stavudine | Tributyrin | L-Ascorbic acid | Paeonol | Sodium 4-phenylbutyrate
相关库经典已知活性库 | 抗癌活性化合物库 | 抗癌化合物库 | 已知活性化合物库 | 自噬库 | 细胞凋亡化合物库 | NO PAINS 化合物库 | 核受体化合物库 | 共价抑制剂库 | 神经元分化化合物库
WYC209|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (12年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 WYC209相关厂家报价

内容声明
拨打电话 立即询价